I've invested in a few smallish ($200M to $2B) biotechs over the past decade or so. While I eventually got out with a small profit, I have sworn off ever investing in one again.
Too much time and too many grey hairs from following the hope-and-disappointment cycle as you read the tea leaves from ambiguous trial results and FDA announcements.
Mesoblast. I won't bother to share the full story of all this company's ups and downs over the last decade but let's just say that the amount of time I spent tracking the news on it was far out of whack with its importance to my portfolio.
Too much time and too many grey hairs from following the hope-and-disappointment cycle as you read the tea leaves from ambiguous trial results and FDA announcements.